This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
5 Excellent GARP Picks With Cheap PEG Ratio
by Zacks Equity Research
Although PEG ratio is categorized under value investing, this strategy follows the principles of both growth and value investing.
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019
by Ekta Bagri
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Why Is Regeneron (REGN) Up 2.4% Since Last Earnings Report?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status
by Zacks Equity Research
Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
by Zacks Equity Research
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
Biotech Stock Outlook: Approval of New Drugs to Boost Performance
by Zacks Equity Research
While decline in sales of high-profile drugs and competitive pressure are likely to weigh on the biotech sector, we expect approval of new drugs to offset the impact of the same.
Regeneron (REGN) Rides on Eylea and Dupixent's Performance
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
The Zacks Analyst Blog Highlights: PetroChina, NextEra, Eni, Dr Pepper and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PetroChina, NextEra, Eni, Dr Pepper and Regeneron
Top Stock Reports for PetroChina, NextEra & Eni
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PetroChina (PTR), NextEra (NEE) and Eni (E).
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
by Zacks Equity Research
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
What's in the Cards for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.
Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) Q3 loss betters estimates. Also, revenues match the consensus mark.
Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR
by Ryan McQueeney
Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.
September JOLTS Report In Spotlight
by Zacks Equity Research
September JOLTS Report In Spotlight
Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings
by Mark Vickery
We won't get the final numbers until later, so until then we're just playing the waiting game.
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 12.67% and 0.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Regeneron (REGN) Might Surprise This Earnings Season
by Zacks Equity Research
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
Is a Disappointment in Store for bluebird (BLUE) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when bluebird (BLUE) reports third-quarter results.